Pharmacologic Dose Testosterone to Treat Castration-Resistant Prostate Cancer: Mechanisms of Action and Drivers of Response
Technical Report,30 Sep 2018,29 Sep 2019
University of Washington Seattle United States
Pagination or Media Count:
Single-arm studies have demonstrated preliminary signs of efficacy for intermittent pharmacologic dose testosterone i.e. Bipolar Androgen Therapy BAT in treating advanced prostate cancer. In this project, we will conduct detailed molecular assessments on biospecimens i.e. blood, metastatic tissue from men receiving BAT to determine somatic and germline factors that predict for responseresistance. We will also evaluate additional PDT-based regimens e.g. combinatorial treatments in preclinical models. This annual technical progress report details progress made during the first year of funding for this project 30 Sep 2018 1 Oct2019. During Year 3 we have continued to collect biospecimens from men enrolled to studies testing BAT. We have published correlative research showing responses to BAT are enriched in patients with mutations in DNA damage repair DDR genes. Preclinical studies have supported the hypothesis that DDR abnormalities predict for response to BAT and have also shown that responses are enhanced when BAT is given in combination with PARP inhibition.
- Medicine and Medical Research